Patents Assigned to Hanmi Pharmaceutical Co., Ltd.
-
Publication number: 20190284299Abstract: The present invention provides a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., bispecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can simultaneously bind two target molecules and are more potent in the treatment of complex diseases.Type: ApplicationFiled: September 28, 2017Publication date: September 19, 2019Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jiawang LIU, Nanmeng SONG, Dongge YANG, Yaping YANG, Maengsup KIM
-
Publication number: 20190194198Abstract: The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-?, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.Type: ApplicationFiled: June 30, 2017Publication date: June 27, 2019Applicant: HANMI PHARMACEUTICAL CO., LTD.Inventors: Kyung Ik LEE, Young Hee JUNG, Ji Young SONG, Seung Ah JUN
-
Patent number: 10322108Abstract: Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a ROR? mediated disease. The compound has the structural formula (I).Type: GrantFiled: January 22, 2016Date of Patent: June 18, 2019Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.Inventors: Hai Xue, Tao Zhao, Mi Young Cha, Maengsup Kim
-
Publication number: 20190152973Abstract: The present invention relates to a novel heterocyclic derivative compound and a use thereof, and in particular, to a novel heterocyclic derivative compound having selective inhibitory activity for a fibroblast growth factor receptor (FGFR) and a pharmaceutical composition including the same preventing and treating various diseases relating to the FGFR.Type: ApplicationFiled: June 28, 2017Publication date: May 23, 2019Applicant: HANMI PHARMACEUTICAL CO., LTD.Inventors: Moon Sub LEE, Eun Young BYUN, Ji Sook KIM, Won Jeoung KIM, Nam Du KIM, Seung Hyun JUNG, Young Gil AHN
-
Patent number: 10273242Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).Type: GrantFiled: October 31, 2017Date of Patent: April 30, 2019Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jinming Liu, Mi Young Cha, Gong Li, Zhanmei Li, Hongjuan Qiu, Maengsup Kim
-
Publication number: 20180244677Abstract: Disclosed are a compound related to inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (especially humans). The compound has a structural formula I.Type: ApplicationFiled: August 12, 2016Publication date: August 30, 2018Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jiangcheng XU, Qinguan CAI, Mi Young CHA, Maengsup KIM
-
Publication number: 20180051036Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).Type: ApplicationFiled: October 31, 2017Publication date: February 22, 2018Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jinming LIU, Mi Young CHA, Gong LI, Zhanmei LI, Hongjuan QIU, Maengsup KIM
-
Publication number: 20170368028Abstract: Disclosed are a compound, a stereisomer and a tautomer thereof, a pharmaceutically acceptable salt thereof, and a solvate or a prodrug thereof, which can be used for preventing or treating a ROR? mediated disease. The compound has the structural formula (I).Type: ApplicationFiled: January 22, 2016Publication date: December 28, 2017Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Hai Xue, Tao Zhao, Mi Young Cha, Maengsup Kim
-
Patent number: 9840517Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).Type: GrantFiled: September 18, 2014Date of Patent: December 12, 2017Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jinming Liu, Mi Young Cha, Gong Li, Zhanmei Li, Hongjuan Qiu, Maengsup Kim
-
Patent number: 9789202Abstract: A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency.Type: GrantFiled: September 5, 2012Date of Patent: October 17, 2017Assignees: HANMI SCIENCE CO., LTD., BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Sung Youb Jung, Young Eun Woo, Se Young Lim, In Young Choi, Jae Ho Lee, Se Chang Kwon, Sung Hwan Moon, Jiawang Liu
-
Publication number: 20160340422Abstract: The present invention provides a bifunctional fusion protein comprising the extracellular region of CTLA4 and an anti-IL-17 antibody, a gene encoding the protein, a vector comprising the gene, a host cell comprising the vector, and a pharmaceutical composition containing the protein.Type: ApplicationFiled: January 28, 2015Publication date: November 24, 2016Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Guoqiang Chen, Jiawang Liu, Nanmeng Song, Yaping Yang, Mi Young Cha
-
Patent number: 9453062Abstract: The present invention provides a GIP analog, which is derived from GIP (1-29, SEQ ID NO: 1), has both GLP-1 agonist activity and GIPR stimulation activity, and comprises an amino acid sequence represented by the following formula I: Tyr-A2-A3-Gly-Thr-Phe-A7-Ser-Asp-Tyr-Ser-A12-A13-A14-A15-Lys-A17-A18-A19-A20-A21-A22-A23-A24-Trp-Leu- A27-A28-A29-Y. The present invention also provides a pharmaceutical composition comprising the GIP analog and use thereof.Type: GrantFiled: June 8, 2012Date of Patent: September 27, 2016Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.Inventors: Tao Ma, Shusen Xu, Zhijun Liu, Bo Zhang, Ning Shen, Hai Yang, Wei Zhang, Yuhua Li, Sunghwan Moon, Maengsup Kim
-
Publication number: 20160229865Abstract: The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).Type: ApplicationFiled: September 18, 2014Publication date: August 11, 2016Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jinming Liu, Mi Young Cha, Gong Li, Zhanmei Li, Hongjuan Qiu, Maengsup Kim
-
Publication number: 20140219961Abstract: A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency.Type: ApplicationFiled: September 5, 2012Publication date: August 7, 2014Applicants: BEIJING HANMI PHARMACEUTICAL CO., LTD., HANMI SCIENCE CO., LTD.Inventors: Sung Youb Jung, Young Eun Woo, Se Young Lim, In Young Choi, Jae Ho Lee, Se Chang Kwon, Sung Hwan Moon, Jiawang Liu
-
Publication number: 20140163226Abstract: The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.Type: ApplicationFiled: June 29, 2012Publication date: June 12, 2014Applicant: HANMI PHARMACEUTICAL CO., LTD.Inventors: Chul Hyun Park, Won Jeoung Kim, Young Hee Jung, Nam Du Kim, Young Kil Chang, Maeng Sup Kim
-
Publication number: 20140162945Abstract: The present invention provides a GIP analog, which is derived from GIP (1-29, SEQ ID NO: 1), has both GLP-1 agonist activity and GIPR stimulation activity, and comprises an amino acid sequence represented by the following formula I: Tyr-A2-A3-Gly-Thr-Phe-A7-Ser-Asp-Tyr-Ser-A12-A13-A14-A15-Lys-A17-A18-A19-A20-A21-A22-A23-A24-Trp-Leu-A27-A28-A29-Y. The present invention also provides a pharmaceutical composition comprising the GIP analog and use thereof.Type: ApplicationFiled: June 8, 2012Publication date: June 12, 2014Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Tao Ma, Shusen Xu, Zhijun Liu, Bo Zhang, Ning Shen, Hai Yang, Wei Zhang, Yuhua Li, Sunghwan Moon, Maengsup Kim
-
Publication number: 20100330108Abstract: The present invention relates to a composition for treating obesity-related diseases comprising an insulinotropic peptide conjugate, more particularly, to a composition for treating obesity-related diseases comprising a conjugate prepared by covalently linking the insulinotropic peptide with a carrier substance via a non-peptidyl linker, and a method for treating obesity-related diseases by using the same. In particular, the composition for treating obesity-related diseases according to the present invention remarkably improves the efficacy of suppressing food intake and its duration to reduce body weight and body fat, thereby being useful for the treatment of obesity-related diseases.Type: ApplicationFiled: November 28, 2008Publication date: December 30, 2010Applicant: HANMI PHARMACEUTICAL CO., LTD.Inventors: Dae Hae Song, Min Young Kim, Young Jin Park, Eun Hee Kang, Sung Youb Jung, Se Chang Kwon, Gwan Sun Lee
-
Publication number: 20100204451Abstract: The present invention relates to an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to a pharmaceutical composition comprising the same. The insulinotropic peptide derivatives according to the present invention exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same according to the present invention can be effectively provided for the treatment of the diseases.Type: ApplicationFiled: July 16, 2008Publication date: August 12, 2010Applicant: HANMI PHARMACEUTICAL CO., LTD.Inventors: Sung Youb Jung, Chang Ki Lim, Dae Hae Song, Sung Min Bae, Young Hoon Kim, Se Chang Kwon, Gwan Sun Lee
-
Publication number: 20100120089Abstract: Disclosed herein is an inducible high-expression cassette comprising a dihydrofolate reductase (DHFR) promoter from which GC-rich repeat sequences are partially or entirely removed, the cassette capable of more effectively improving a gene amplification system. Also disclosed are an expression vector comprising the inducible expression cassette and optionally a gene encoding a recombinant protein of interest, an animal cell line transformed with the expression vector, and a method of mass producing and purifying a recombinant protein by culturing the transformant. The present invention enables the shortening of the time required to establish a cell line producing a recombinant protein of interest at high levels using a low concentration of a DHFR inhibitor, thereby allowing more effective production of the recombinant protein.Type: ApplicationFiled: October 16, 2007Publication date: May 13, 2010Applicant: HANMI PHARMACEUTICAL CO., LTD.Inventors: In Young Choi, Chang Hwan Kim, Hyun Ji Lee, Seong Hee Park, Se Chang Kwon, Gwan Sun Lee
-
Publication number: 20100105877Abstract: The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and an immunoglobulin Fc region, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long acting formulations of various peptide drugs.Type: ApplicationFiled: January 4, 2008Publication date: April 29, 2010Applicant: HANMI PHARMACEUTICAL CO., LTD.Inventors: Dae Hae Song, Chang Ki Lim, Tae Hun Song, Young Hoon Kim, Se Chang Kwon, Gwan Sun Lee, Sung Youb Jung, In Young Choi